PE/VC  Perceptive Advisors

https://www.perceptivelife.com/





     Office Locations:

51 Astor Place, 10th Floor
New York, NY 10003
Phone: 646-205-5300

 

Stages:

  • Early
  • Middle Market


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $7.3 billion across their strategies. Perceptive Advisors has made global investments in public and private companies developing biotechnology products, drugs, medical devices and diagnostics. Perceptive established its Credit Opportunities strategy with the launch of its first closed-end fund in 2013. The firm currently manages approximately $1 Billion of capital dedicated to private credit, and provide customized debt financing solutions to innovative healthcare companies. Perceptive seeks to invest $10 - $100M for credit investments. Perceptive Advisors announced (May of 2021) the final closing of Perceptive Xontogeny Venture Fund II, LP (PXV Fund II) with $515 million in capital commitments in an oversubscribed fund to further the firm's early-stage life sciences platform.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Adam Stone Chief Investment Officer
    Bill Schwieterman Managing Director
    Craig Yeshion MD Managing Director
    Ellen Hukkelhoven PhD Managing Director
    Fred Callor Corporate Development, Venture

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      10/05/2021


      Honor Technology


      CA


      $370,000,000


      Venture Debt & Equity


      09/08/2021


      A-Alpha Bio


      WA


      $20,000,000


      Series A


      09/08/2021


      HilleVax


      MA


      $135,000,000


      Crossover Financing


      08/30/2021


      Genome Medical


      CA


      $60,000,000


      Series C


      07/20/2021


      Amylyx Pharmaceuticals


      MA


      $135,000,000


      Series C


      05/12/2021


      Juno Diagnostics


      CA


      $25,000,000


      Series A


      04/07/2021


      Icosavax


      WA


      $100,000,000


      Series B


      03/31/2021


      Scribe Therapeutics


      CA


      $100,000,000


      Series B


      03/30/2021


      Pyxis Oncology


      MA


      $152,000,000


      Series B


      02/11/2021


      Day One Biopharmaceuticals


      CA


      $130,000,000


      Series B


      02/11/2021


      Pipeline Therapeutics


      CA


      $80,000,000


      Series C


      01/13/2021


      Impulse Dynamics


      NJ


      $60,000,000


      Series D


      01/07/2021


      IsoPlexis


      CT


      $135,000,000


      Series D


      12/16/2020


      Neuron23


      CA


      $113,500,000


      Series A and B


     

    Portfolio companies include:


      4D Molecular Therapeutics
        web link


      A-Alpha Bio
        web link


      AavantiBio
        web link


      Amylyx Pharmaceuticals
        web link


      AsclepiX Therapeutics
        web link


      Athira Pharma
        web link


      Avidity Biosciences
        web link


      Blueprint Medicines
        web link


      BridgeBio Pharma
        web link


      C4 Therapeutics
        web link


      Day One Biopharmaceuticals
        web link


      Freenome
        web link


      Genome Medical
        web link


      HilleVax
        web link


      Honor Technology
        web link


      Icosavax
        web link


      IDEAYA Biosciences
        web link


      Impulse Dynamics
        web link


      Invitae


      IsoPlexis
        web link


      Juno Diagnostics
        web link


      Kindbody
        web link


      Landos Biopharma
        web link


      Lyra Therapeutics
        web link


      Nautilus Biotechnology
        web link


      Neuron23
        web link


      Nuvation Bio
        web link


      Oncobiologics
        web link


      Oncorus
        web link


      Orchard Therapeutics
        web link


      Orchestra BioMed
        web link


      Otonomy
        web link


      Outset Medical


      PanTheryx
        web link


      Partner Therapeutics
        web link


      Pipeline Therapeutics
        web link


      Poseida Therapeutics
        web link


      Pyxis Oncology
        web link


      REGENXBIO
        web link


      Relay Therapeutics
        web link


      Renovia
        web link


      Scribe Therapeutics
        web link


      SpringWorks Therapeutics
        web link


      Stoke Therapeutics
        web link


      Taysha Gene Therapies
        web link


      True North Therapeutics
        web link


      Unum Therapeutics
        web link


      Virobay
        web link


      Willow
        web link


      Xontogeny
        web link


      Zentalis Pharmaceuticals
        web link


     

    Recent News: